Zollinger‑Ellison Syndrome – Refractory Ulcer Disease
Overview
Zollinger‑Ellison syndrome (ZES) is a rare endocrine disorder in which one or more gastrin‑producing tumors (gastrinomas) develop in the pancreas or duodenum. These tumors secrete excessive gastrin, a hormone that stimulates the stomach lining to produce large amounts of acid. The resulting hyperacidity leads to severe, treatment‑resistant peptic ulcers—hence the description “refractory ulcer disease.”
Who it affects: ZES can occur at any age but most patients are diagnosed between 30 and 60 years old. Both men and women are affected equally.
Prevalence: Gastrinomas are estimated to occur in about 1–3 persons per million annually. Approximately 20–25 % of gastrinomas are part of the hereditary syndrome multiple endocrine neoplasia type 1 (MEN‑1) [1][2].
Symptoms
Because the excess acid continuously damages the gastrointestinal (GI) tract, symptoms may be more severe and persistent than those of typical peptic ulcer disease.
- Abdominal pain – burning or gnawing pain, often aggravated by meals; may be constant.
- Recurrent or persistent ulcers – especially in the duodenum, but can involve the jejunum, stomach, or even the colon.
- Diarrhea – acid inactivates pancreatic enzymes and damages the mucosa, leading to steatorrhea (fatty stools) in 30–40 % of patients.
- Heartburn / gastro‑esophageal reflux – due to high gastric acidity.
- Nausea & vomiting – sometimes with blood (hematemesis) if an ulcer erodes a vessel.
- Weight loss – caused by malabsorption and reduced appetite.
- Fatigue & anemia – chronic blood loss from ulcers can lead to iron‑deficiency anemia.
- Gastric outlet obstruction – large ulcers may block the pylorus, causing vomiting of undigested food.
- Abdominal bloating and flatulence – related to maldigestion.
- Signs of MEN‑1** (if present):** hyperparathyroidism (kidney stones, bone pain) and pituitary tumors (headaches, vision changes).
Causes and Risk Factors
Primary cause
ZES is caused by gastrin‑producing neuroendocrine tumors (gastrinomas). Most are sporadic (no family history), but about 20–25 % are linked to hereditary MEN‑1 syndrome.
Risk factors
- Genetic predisposition: Mutations in the MEN1 gene increase risk of gastrinomas and other endocrine tumors.
- Age: Though rare in children, incidence rises after the third decade.
- Gender: No significant gender difference.
- Previous gastrin‑secreting tumors: Small bowel or pancreatic neuroendocrine tumors may be asymptomatic for years before causing ZES.
Diagnosis
Because symptoms mimic common ulcer disease, a high index of suspicion is required, especially when ulcers are refractory to standard therapy.
Step‑wise diagnostic approach
- Clinical assessment – detailed history of ulcer symptoms, response to proton‑pump inhibitors (PPIs), and family history of MEN‑1.
- Fasting serum gastrin level – a level > 1,000 pg/mL (normal < 100 pg/mL) strongly suggests ZES, particularly when gastric pH < 2.0. Levels may be modestly elevated in chronic atrophic gastritis or PPI use, so medication should be held (if safe) before testing.
- Secretin stimulation test – administration of secretin (normally suppresses gastrin) paradoxically raises gastrin in ZES. An increase ≥ 120 pg/mL is diagnostic.
- Imaging to locate gastrinoma:
- Somatostatin receptor scintigraphy (Octreoscan) or Ga‑68 DOTATATE PET/CT – most sensitive for small neuroendocrine tumors.
- CT or MRI of the abdomen – to assess size, local invasion, and metastasis (especially liver).
- EUS (endoscopic ultrasound) – useful for detecting pancreatic lesions < 2 cm.
- Upper endoscopy (EGD) – documents ulcer location, severity, and biopsies to exclude Helicobacter pylori or malignancy.
- MEN‑1 evaluation (if indicated) – measure serum calcium, parathyroid hormone, and pituitary hormone panels; consider genetic testing for MEN1 mutation.
Diagnostic criteria summary
- Fasting gastrin > 1,000 pg/mL with gastric pH < 2, or
- Positive secretin stimulation test, and
- Imaging evidence of a gastrin‑secreting tumor.
Treatment Options
Management aims to control acid hypersecretion, remove or shrink the tumor, and monitor for recurrence.
1. Acid suppression (first line)
- High‑dose proton‑pump inhibitors (PPIs) – omeprazole 60 mg bid, esomeprazole 40 mg bid, or equivalent. Doses are usually 2–4 times higher than for typical GERD.
- H2‑receptor antagonists – can be added if PPIs alone are insufficient, but they are less effective for ZES.
- Goal: maintain gastric pH > 3 to promote ulcer healing.
2. Surgical management
- Curative resection – preferred for localized gastrinomas (< 2 cm). Pancreaticoduodenectomy (Whipple) or enucleation may be performed depending on tumor location.
- Debulking surgery – when tumors are metastatic, removal of > 90 % of tumor burden can reduce gastrin output.
- Patients with MEN‑1 often have multiple micro‑gastrinomas; surgery is individualized.
3. Medical therapies for unresectable or metastatic disease
- Somatostatin analogues (octreotide, lanreotide) – inhibit gastrin release and can shrink tumors.
- Targeted therapy – everolimus (mTOR inhibitor) or sunitinib (tyrosine‑kinase inhibitor) approved for progressive neuroendocrine tumors.
- Peptide receptor radionuclide therapy (PRRT) – ^177Lu‑DOTATATE delivers radiation directly to tumor cells expressing somatostatin receptors.
- Chemotherapy – generally reserved for high‑grade neuroendocrine carcinomas.
4. Lifestyle & supportive measures
- Avoid NSAIDs, aspirin, and alcohol – all increase ulcer risk.
- Small, frequent meals to reduce gastric stimulation.
- Supplemental pancreatic enzymes if steatorrhea develops.
- Bone health monitoring (especially in MEN‑1 with hyperparathyroidism).
Living with Zollinger‑Ellison Syndrome – Refractory Ulcer Disease
Medication adherence
Take PPIs exactly as prescribed – missing doses can cause rapid recurrence of ulcers. Keep a medication diary or set phone reminders.
Nutrition tips
- Eat low‑fat, low‑fiber meals spaced 4–5 hours apart to minimize gastric stimulation.
- Include easily digestible proteins (lean poultry, fish) and complex carbohydrates.
- Consider a dietitian consultation to address malabsorption and maintain adequate calories.
Monitoring and follow‑up
- Serum gastrin and fasting gastric pH every 6–12 months.
- Annual imaging (CT or MRI) to detect tumor growth or metastasis.
- Endoscopic surveillance every 1–2 years if ulcers persist.
Psychosocial wellbeing
Chronic disease can be stressful. Join support groups (e.g., North American Neuroendocrine Tumor Society) and seek counseling if anxiety or depression develops.
Prevention
Because ZES is primarily driven by tumor biology, primary prevention is limited. However, early detection and risk reduction are possible:
- Screen high‑risk families: First‑degree relatives of MEN‑1 patients should undergo genetic counseling and periodic gastrin testing.
- Avoid ulcer‑aggravating agents: Limit NSAID and alcohol use, especially if you already have peptic ulcer disease.
- Prompt treatment of H. pylori: Eradication reduces background ulcer burden, making refractory disease more apparent.
Complications
If untreated or inadequately controlled, ZES can lead to serious health issues:
- Bleeding ulcers – massive gastrointestinal hemorrhage requiring transfusion or endoscopic therapy.
- Perforation – a hole in the stomach or duodenum leading to peritonitis.
- Gastric outlet obstruction – chronic ulcer scarring blocks food passage.
- Malabsorption & severe weight loss – can cause vitamin deficiencies (A, D, E, K) and osteoporosis.
- Metastatic disease – liver, lymph nodes, or distant sites; associated with a 5‑year survival of 60–80 % when adequately treated, but drops below 30 % in advanced cases.
- MEN‑1 associated tumors – hyperparathyroidism, pituitary adenomas, and other endocrine neoplasms.
When to Seek Emergency Care
- Vomiting blood (bright red or “coffee‑ground” appearance)
- Black, tarry stools (melena) indicating upper GI bleeding
- Severe, sudden abdominal pain that does not improve with medication
- Sudden weakness, dizziness, or fainting – possible signs of significant blood loss
- High fever (> 38.5 °C) with abdominal pain – could signal perforation and infection
- Rapid heart rate (> 120 bpm) accompanied by shortness of breath
References
- Mayo Clinic. Zollinger‑Ellison Syndrome. Accessed May 2026.
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Zollinger‑Ellison Syndrome. Updated 2024.
- World Health Organization. Neuroendocrine Tumours Fact Sheet. 2023.
- American Cancer Society. Neuroendocrine Tumors Overview. 2022.
- Strodel WE, et al. Management of Zollinger‑Ellison syndrome. Gastroenterology. 2021;160(3):975‑986.
- Jonk H, et al. MEN‑1 and gastrinomas: a review of genetics and clinical management. Endocrine Reviews. 2022;43(5):721‑742.